Sodium risedronate
Sodium risedronate Basic information
- Product Name:
- Sodium risedronate
- Synonyms:
-
- RISEDREMATE SODIUM
- RISEDRONATE NA
- RISEDRONATE SODIUM
- RISEDRONIC ACID, SODIUM SALT
- SODIUM RISEDRONATE
- [1-hydroxy-2-(3-pyridinyl)ethylidene]-bis[phosphonic acid] monosodium salt
- (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-phosphonicacimonosodiumsalt
- risedronate,RID
- CAS:
- 115436-72-1
- MF:
- C7H12NNaO7P2
- MW:
- 307.11
- EINECS:
- 1806241-263-5
- Product Categories:
-
- BELCOMYCINE
- All Inhibitors
- Osteoporosis
- Inhibitors
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Active Pharmaceutical Ingredients
- Bone Resorption Inhibitor
- Phosphorylating and Phosphitylating Agents
- Heterocycles
- Mol File:
- 115436-72-1.mol
Sodium risedronate Chemical Properties
- Melting point:
- 252-262°C
- storage temp.
- room temp
- solubility
- H2O: soluble5mg/mL, clear (warmed)
- form
- powder
- color
- white to beige
- Water Solubility
- Soluble to 10 mM in water
- BCS Class
- 3
- Stability:
- Hygroscopic
- CAS DataBase Reference
- 115436-72-1(CAS DataBase Reference)
Safety Information
- Risk Statements
- 62-64
- Safety Statements
- 20-22-36/37
- WGK Germany
- 3
- RTECS
- SZ8567500
- HS Code
- 29333990
Sodium risedronate Usage And Synthesis
Description
Risedronate sodium is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism.
Risedronate sodium is used for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures, treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures, treatment of osteoporosis in men at high risk of fractures, and treatment of Paget’s disease. It is marketed as Actonel (tablet) and Atelvia (delayed-release tablet).
References
[1] https://www.medicines.org.uk
[2] http://www.rxlist.com
[3] http://www.healthline.com
Description
Risedronate sodium was launched as Actonel in the US for treatment of Paget's disease. Risedronic acid is readily obtained by condensation of 2-(3- pyridyl)acetic acid with phosphorous acid in presence of phosphorus oxychloride. Risedronate sodium is an orally active bisphosphonate of third generation, showing more potent bone antiresorptive properties than most of prior bisphosphonates like etidronate which has been used for the same indication since 1978. The biological mechanism by which Risedronate, and generally bisphosphonates, act is not quite clear presently ; recent advances have suggested that aminobisphosphonates interfere with the HMG-CoA pathway and inhibit protein prenylation, causing apoptosis of osteoclasts and macrophages. These apoptotic effects are correlated to the anti-resorptive properties of this class of compounds. In a 2 month clinical trial involving patients with Paget's desease, 30 mg risedronate daily achieved an appreciable reduction of serum alkaline phosphatase levels, an indicator of bone stabilization, in 77% of patients, compared with 11% on etidronate at 400 mg daily for 6 months. Risedronate is also in development for the treatment and prevention of various bone diseases, particularly post-menopausal and corticosteroid-induced osteoporosis.
Chemical Properties
Fine White to Off-White Crystalline Powder
Originator
Procter Gamble (US)
Uses
antibacterial
Uses
Osteoporosis
Uses
Risedronic Acid is a pyridinyl biphosphonate bone resorption inhibitor.
Definition
ChEBI: Risedronate sodium is a 1,1-bis(phosphonic acid).
brand name
Actonel (Procter & Gamble).
Hazard
Human systemic effects.
Biological Activity
Orally active biphosphonate that inhibits farnesyl diphosphate (FPP) synthase. Exhibits antiproliferative and proapoptotic activity in numerous tumor cell lines and inhibits osteoclast-mediated bone reabsorption in vivo .
Biochem/physiol Actions
Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.
Clinical Use
Bisphosphonate:
Treatment and prevention of osteoporosis (including
corticosteroid induced)
Paget’s disease
Drug interactions
Potentially hazardous interactions with other drugs
Calcium-containing substances: avoid for 2 hours
before and after administration.
Metabolism
The mean bioavailability of risedronate is 0.63% in
the fasting state, and there is no evidence of systemic
metabolism of risedronate sodium.
About half of the absorbed portion is excreted in the
urine within 24 hours; the remainder is sequestered
to bone for a prolonged period. Unabsorbed drug is
eliminated unchanged in the faeces.
storage
Store at RT
Sodium risedronateSupplier
- Tel
- 0523-86976638
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- +86 351 7031519
- sales@RHFChem.com
Sodium risedronate(115436-72-1)Related Product Information
- Ibandronate sodium monohydrate
- Alendronate sodium
- Sodium sulfate
- Diclofenac sodium
- Clodronate disodium
- Disodium pamidronate
- Sodium benzoate
- Folic acid
- Risedronic acid
- Citric acid
- CHLOROPHOSPHONAZO III
- Sodium chloride
- Sodium hydroxide
- Ethyl 2-(Chlorosulfonyl)acetate
- Sodium citrate
- Pamidronate disodium salt
- Sodium acetate
- Sodium bicarbonate